Examkin

Question

Difficulty: HardInfectious Diseases

During morning rounds, the care team reviews the progress of a 34-year-old female patient admitted two days ago with complicated urinary tract infection.

Vital signs at admission were:
- Temperature: 39.4°C (102.9°F)
- Blood pressure: 92/58 mm Hg
- Pulse: 115/min

She received intravenous fluid resuscitation and empiric therapy with intravenous piperacillin-tazobactam. Today, the patient reports feeling much better, noting her flank pain has nearly resolved and she is eating a regular diet. Current vital signs show a temperature of 37.0°C (98.6°F), blood pressure of 116/74 mm Hg, and a pulse of 78/min.

The microbiology laboratory updates the results from the admission urine and blood cultures. Both are positive for *Escherichia coli*. The isolate demonstrates the following susceptibility profile:

AntimicrobialResult
AmpicillinResistant
CeftriaxoneSusceptible
CiprofloxacinSusceptible
MeropenemSusceptible
Piperacillin-tazobactamSusceptible
Trimethoprim-sulfamethoxazoleSusceptible

Based on these findings, which of the following is the most appropriate next step in the management of this patient's infection?

  1. Discontinue piperacillin-tazobactam and initiate oral trimethoprim-sulfamethoxazoleAnswer
  2. B
    Continue intravenous piperacillin-tazobactam for the remainder of the treatment course
  3. C
    Discontinue piperacillin-tazobactam and initiate intravenous ceftriaxone
  4. D
    Discontinue piperacillin-tazobactam and initiate intravenous meropenem
  5. E
    Add intravenous gentamicin to the current regimen

Answer

Discontinue piperacillin-tazobactam and initiate oral trimethoprim-sulfamethoxazole.
The patient has bacteremic pyelonephritis but has achieved clinical stability, as evidenced by being afebrile, having normalized hemodynamics, and tolerating oral intake. At this stage, the standard of care dictates transitioning from intravenous to oral antibiotics to minimize hospital length of stay and reduce risks associated with intravenous catheters. Oral trimethoprim-sulfamethoxazole is a highly bioavailable, targeted, narrow-spectrum agent that achieves excellent tissue penetration in the urinary tract and is effective against the isolated *E. coli* strain.

Step-by-Step Solution

1
Evaluate the patient's current clinical status.
The patient is afebrile for at least 24 hours, hemodynamically stable, and tolerating oral intake.
These findings fulfill the standard criteria for transitioning a patient from intravenous to oral antimicrobial therapy.
2
Analyze the microbiology culture and susceptibility results.
The infection is caused by an *E. coli* strain that is susceptible to several highly bioavailable oral agents, including ciprofloxacin and trimethoprim-sulfamethoxazole.
Culture data must be used to select the narrowest effective targeted therapy, adhering to antimicrobial stewardship guidelines.
3
Synthesize clinical and microbiological data to select the optimal regimen.
Oral trimethoprim-sulfamethoxazole is selected over continuing intravenous or broad-spectrum options.
This choice provides targeted coverage, minimizes unnecessary exposure to broad-spectrum agents, and allows for the removal of intravenous catheters to facilitate hospital discharge.

Key Concept

Antimicrobial stewardship in severe infections includes timely de-escalation based on susceptibility data and transitioning from intravenous to highly bioavailable oral therapy as soon as clinical stability is achieved.
Rate this question

Topics

Infectious Diseases

More questions from this topic